title: Bridged androstenediol analogs as ER-beta selective SERMs.
abstract: A series of bridged androstenediol derivatives was prepared. The bridged compounds exhibited reduced ER-beta selectivity relative to uncyclized analogs.
authors: Merck Research Laboratories, PO Box 2000, Rahway, NJ 07065, USA. tim_blizzard@merck.com
authors: Timothy A
authors: TA
authors: Blizzard
authors: Candido
authors: C
authors: Gude
authors: Wanda
authors: W
authors: Chan
authors: Elizabeth T
authors: ET
authors: Birzin
authors: Marina
authors: M
authors: Mojena
authors: Consuelo
authors: C
authors: Tudela
authors: Fang
authors: F
authors: Chen
authors: Kristin
authors: K
authors: Knecht
authors: Qin
authors: Q
authors: Su
authors: Bryan
authors: B
authors: Kraker
authors: Mark A
authors: MA
authors: Holmes
authors: Susan P
authors: SP
authors: Rohrer
authors: Milton L
authors: ML
authors: Hammond
mesh_terms: D000734:Androstenediols / Q000138:chemical synthesis* / Q000494:pharmacology; D003500:Cyclization; D047629:Estrogen Receptor beta / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000378:metabolism; D006801:Humans; D008958:Models, Molecular; D015394:Molecular Structure; D020845:Selective Estrogen Receptor Modulators / Q000138:chemical synthesis* / Q000494:pharmacology*; D013329:Structure-Activity Relationship
chemical_list: D000734:Androstenediols; D047629:Estrogen Receptor beta; D020845:Selective Estrogen Receptor Modulators